Amylyx Pharmaceuticals, Inc. financial data

Symbol
AMLX on Nasdaq
Location
43 Thorndike Street, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.01K % +108%
Quick Ratio 44.6 %
Debt-to-equity 12.1 % -51.4%
Return On Equity -69 % +19.3%
Return On Assets -61.5 % +10%
Operating Margin 23.7K %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 110M shares +60.2%
Common Stock, Shares, Outstanding 110M shares +60.1%
Entity Public Float 118B USD +8877%
Common Stock, Value, Issued 11K USD +57.1%
Weighted Average Number of Shares Outstanding, Basic 93.3M shares +37.1%
Weighted Average Number of Shares Outstanding, Diluted 93.3M shares +37.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax -665K USD -100%
Research and Development Expense 92.1M USD -27%
Costs and Expenses 157M USD -66.6%
Operating Income (Loss) -157M USD +42.2%
Nonoperating Income (Expense) 7.42M USD -49.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -150M USD +41.8%
Income Tax Expense (Benefit) -635K USD -132%
Net Income (Loss) Attributable to Parent -149M USD +42.5%
Earnings Per Share, Basic -1 USD/shares +53.1%
Earnings Per Share, Diluted -1 USD/shares +53.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 225M USD +213%
Marketable Securities, Current 119M USD -26.9%
Accounts Receivable, after Allowance for Credit Loss, Current 132K USD -92.4%
Inventory, Net 38.3M USD +292%
Assets, Current 353M USD +44.1%
Property, Plant and Equipment, Net 399K USD -68.1%
Operating Lease, Right-of-Use Asset 5.48M USD +7.37%
Other Assets, Noncurrent 2.5M USD +419%
Assets 363M USD +44.7%
Accounts Payable, Current 5.34M USD +259%
Employee-related Liabilities, Current 9.81M USD
Accrued Liabilities, Current 19.5M USD -61.4%
Liabilities, Current 25.8M USD -52.2%
Operating Lease, Liability, Noncurrent 4.95M USD +733%
Liabilities 30.7M USD -43.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 815K USD +27.1%
Retained Earnings (Accumulated Deficit) -718M USD -26.2%
Stockholders' Equity Attributable to Parent 332M USD +69.2%
Liabilities and Equity 363M USD +44.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -39.8M USD -8044%
Net Cash Provided by (Used in) Financing Activities 65.7M USD +50024%
Net Cash Provided by (Used in) Investing Activities -43.7M USD -5431%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 110M shares +60.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -17.6M USD -5121%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 226M USD +209%
Deferred Tax Assets, Valuation Allowance 159M USD +88.9%
Deferred Tax Assets, Gross 159M USD +86.2%
Operating Lease, Liability 1.98M USD -53.2%
Depreciation 156K USD -50.5%
Payments to Acquire Property, Plant, and Equipment 11K USD -83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -149M USD +42.4%
Lessee, Operating Lease, Liability, to be Paid 2.06M USD -54.6%
Property, Plant and Equipment, Gross 2.32M USD -46.2%
Operating Lease, Liability, Current 981K USD -50.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 476K USD -70%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.59M USD -36%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 82K USD -72.9%
Lessee, Operating Lease, Liability, to be Paid, Year Three 476K USD -70%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.76M USD +70.3%
Operating Lease, Payments 100K USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 607K USD -60.9%
Share-based Payment Arrangement, Expense 28M USD -21.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%